US And Canada

Raghupathy “Siva” Sivakumar has been appointed as the university’s inaugural vice-president of commercialisation and chief commercialisation officer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Based on technology at University of Pennsylvania, iEcure has launched to commercialise gene therapies initially for liver disorders and an option to license more assets.

Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.